Invesco Ltd. Ultragenyx Pharmaceutical Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Invesco Ltd. holds 1,674,269 shares of RARE stock, worth $77.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,674,269

Previous 1,268,318 32.01%

Holding current value

$77.7 Million

Previous $52.1 Million 78.42%

% of portfolio

0.02%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$40.21 - $59.36 $16.3 Million - $24.1 Million	405,951 Added 32.01%	1,674,269 $93 Million
Q2 2024 Aug 13, 2024	BUY	$37.42 - $51.61 $28.6 Million - $39.5 Million	765,466 Added 152.22%	1,268,318 $52.1 Million
Q1 2024 May 14, 2024	BUY	$43.02 - $53.69 $3.13 Million - $3.91 Million	72,834 Added 16.94%	502,852 $23.5 Million
Q4 2023 Feb 12, 2024	BUY	$31.73 - $49.19 $1.41 Million - $2.19 Million	44,577 Added 11.57%	430,018 $20.6 Million
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $282,572 - $377,572	8,092 Added 2.14%	385,441 $13.7 Million
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $11.5 Million - $16.1 Million	308,730 Added 449.92%	377,349 $17.4 Million
Q1 2023 May 12, 2023	SELL	$36.99 - $48.71 $91,772 - $120,849	-2,481 Reduced 3.49%	68,619 $2.75 Million
Q4 2022 Feb 13, 2023	BUY	$33.72 - $46.33 $303,210 - $416,599	8,992 Added 14.48%	71,100 $3.29 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $49,710 - $82,278	-1,244 Reduced 1.96%	62,108 $2.57 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $218,008 - $406,504	4,760 Added 8.12%	63,352 $3.78 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $31.2 Million - $42.3 Million	-501,548 Reduced 89.54%	58,592 $4.26 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $10.6 Million - $12.6 Million	-143,224 Reduced 20.36%	560,140 $47.1 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $19.5 Million - $25.6 Million	249,738 Added 55.05%	703,364 $63.4 Million
Q2 2021 Aug 17, 2021	SELL	$92.19 - $115.71 $338,890 - $425,349	-3,676 Reduced 0.8%	453,626 $43.3 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $13.3 Million - $20.9 Million	-124,678 Reduced 21.42%	457,302 $52.1 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $26.9 Million - $56.4 Million	318,225 Added 120.65%	581,980 $80.6 Million
Q3 2020 Nov 16, 2020	BUY	$72.98 - $90.0 $17.6 Million - $21.8 Million	241,833 Added 1103.15%	263,755 $21.7 Million
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $358,861 - $598,383	7,650 Added 53.6%	21,922 $1.71 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $256,677 - $477,662	7,594 Added 113.72%	14,272 $634,000
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $15,694 - $19,936	-435 Reduced 6.12%	6,678 $285,000
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $11,730 - $17,418	-276 Reduced 3.74%	7,113 $304,000
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $13,952 - $18,887	-254 Reduced 3.32%	7,389 $469,000
Q1 2019 May 15, 2019	SELL	$39.87 - $69.36 $164,782 - $286,664	-4,133 Reduced 35.1%	7,643 $530,000
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $457,968 - $910,284	11,776 New	11,776 $512,000

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.25B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account